Mink therapeutics announces $5.8 million private placement and appointment of board observer

New york, may 13, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has entered into a stock purchase agreement to sell securities in a private placement financing (pipe) for $5.8 million. this capital injection is earmarked for accelerating the clinical trials of mink-215, our leading allogeneic car-inkt cell therapy targeting fibroblast activation protein (fap) in solid tumors, which is planned to enter the clinic in early 2025.
INKT Ratings Summary
INKT Quant Ranking